Ids
stringlengths 36
36
| text
stringlengths 45
2.03k
| label
int64 0
1
|
|---|---|---|
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients who have received hyperthermia to the target area within 10 weeks prior to first dosing of study agent. secondary trial: More than three prior chemotherapy lines for advanced disease. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients who have received hyperthermia to the target area within 10 weeks prior to first dosing of study agent. secondary trial: Symptomatic CNS metastases or evidence of leptomeningeal disease. Previously treated asymptomatic CNS metastases are allowed provided that the last treatment for CNS metastases was completed >8 weeks prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients who have received hyperthermia to the target area within 10 weeks prior to first dosing of study agent. secondary trial: Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients who have received hyperthermia to the target area within 10 weeks prior to first dosing of study agent. secondary trial: Peripheral neuropathy grade 2 at randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients who have received hyperthermia to the target area within 10 weeks prior to first dosing of study agent. secondary trial: Active cardiac disease the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients who have received hyperthermia to the target area within 10 weeks prior to first dosing of study agent. secondary trial: History of cardiac dysfunction the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients who have received hyperthermia to the target area within 10 weeks prior to first dosing of study agent. secondary trial: Any malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients who have received hyperthermia to the target area within 10 weeks prior to first dosing of study agent. secondary trial: Known hypersensitivity to any study medication the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients who have received hyperthermia to the target area within 10 weeks prior to first dosing of study agent. secondary trial: Breastfeeding or pregnant the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with an uncontrolled bleeding disorder. secondary trial: Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with an uncontrolled bleeding disorder. secondary trial: HER2+ status defined as IHC 3+ staining or in situ hybridization positive the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with an uncontrolled bleeding disorder. secondary trial: Patients with resistance to trastuzumab the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with an uncontrolled bleeding disorder. secondary trial: Prior taxane therapy the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with an uncontrolled bleeding disorder. secondary trial: Patients with an ECOG performance status of 0 - 2 the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with an uncontrolled bleeding disorder. secondary trial: Patients with measurable disease as per RECIST criteria the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with an uncontrolled bleeding disorder. secondary trial: Documentation of negative pregnancy test for patients of child bearing potential prior to enrollment within 7 days prior to randomization. Sexually active pre-menopausal women must use adequate contraceptive measures, excluding estrogen containing contraceptives, while on study; the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with an uncontrolled bleeding disorder. secondary trial: Patients must meet laboratory criteria defined in the study within 21 days prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with an uncontrolled bleeding disorder. secondary trial: Prior mTOR inhibitors or vinca alkaloid agents for the treatment of cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with an uncontrolled bleeding disorder. secondary trial: More than three prior chemotherapy lines for advanced disease. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with an uncontrolled bleeding disorder. secondary trial: Symptomatic CNS metastases or evidence of leptomeningeal disease. Previously treated asymptomatic CNS metastases are allowed provided that the last treatment for CNS metastases was completed >8 weeks prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with an uncontrolled bleeding disorder. secondary trial: Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with an uncontrolled bleeding disorder. secondary trial: Peripheral neuropathy grade 2 at randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with an uncontrolled bleeding disorder. secondary trial: Active cardiac disease the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with an uncontrolled bleeding disorder. secondary trial: History of cardiac dysfunction the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with an uncontrolled bleeding disorder. secondary trial: Any malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with an uncontrolled bleeding disorder. secondary trial: Known hypersensitivity to any study medication the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with an uncontrolled bleeding disorder. secondary trial: Breastfeeding or pregnant the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients who will be therapeutically anticoagulated with heparins or coumadin at the time of the biopsy (they are eligible if anticoagulation can be held prior to biopsy as per investigator). Patients on aspirin and other platelet agents are eligible. secondary trial: Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients who will be therapeutically anticoagulated with heparins or coumadin at the time of the biopsy (they are eligible if anticoagulation can be held prior to biopsy as per investigator). Patients on aspirin and other platelet agents are eligible. secondary trial: HER2+ status defined as IHC 3+ staining or in situ hybridization positive the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients who will be therapeutically anticoagulated with heparins or coumadin at the time of the biopsy (they are eligible if anticoagulation can be held prior to biopsy as per investigator). Patients on aspirin and other platelet agents are eligible. secondary trial: Patients with resistance to trastuzumab the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients who will be therapeutically anticoagulated with heparins or coumadin at the time of the biopsy (they are eligible if anticoagulation can be held prior to biopsy as per investigator). Patients on aspirin and other platelet agents are eligible. secondary trial: Prior taxane therapy the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients who will be therapeutically anticoagulated with heparins or coumadin at the time of the biopsy (they are eligible if anticoagulation can be held prior to biopsy as per investigator). Patients on aspirin and other platelet agents are eligible. secondary trial: Patients with an ECOG performance status of 0 - 2 the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients who will be therapeutically anticoagulated with heparins or coumadin at the time of the biopsy (they are eligible if anticoagulation can be held prior to biopsy as per investigator). Patients on aspirin and other platelet agents are eligible. secondary trial: Patients with measurable disease as per RECIST criteria the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients who will be therapeutically anticoagulated with heparins or coumadin at the time of the biopsy (they are eligible if anticoagulation can be held prior to biopsy as per investigator). Patients on aspirin and other platelet agents are eligible. secondary trial: Documentation of negative pregnancy test for patients of child bearing potential prior to enrollment within 7 days prior to randomization. Sexually active pre-menopausal women must use adequate contraceptive measures, excluding estrogen containing contraceptives, while on study; the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients who will be therapeutically anticoagulated with heparins or coumadin at the time of the biopsy (they are eligible if anticoagulation can be held prior to biopsy as per investigator). Patients on aspirin and other platelet agents are eligible. secondary trial: Patients must meet laboratory criteria defined in the study within 21 days prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients who will be therapeutically anticoagulated with heparins or coumadin at the time of the biopsy (they are eligible if anticoagulation can be held prior to biopsy as per investigator). Patients on aspirin and other platelet agents are eligible. secondary trial: Prior mTOR inhibitors or vinca alkaloid agents for the treatment of cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients who will be therapeutically anticoagulated with heparins or coumadin at the time of the biopsy (they are eligible if anticoagulation can be held prior to biopsy as per investigator). Patients on aspirin and other platelet agents are eligible. secondary trial: More than three prior chemotherapy lines for advanced disease. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients who will be therapeutically anticoagulated with heparins or coumadin at the time of the biopsy (they are eligible if anticoagulation can be held prior to biopsy as per investigator). Patients on aspirin and other platelet agents are eligible. secondary trial: Symptomatic CNS metastases or evidence of leptomeningeal disease. Previously treated asymptomatic CNS metastases are allowed provided that the last treatment for CNS metastases was completed >8 weeks prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients who will be therapeutically anticoagulated with heparins or coumadin at the time of the biopsy (they are eligible if anticoagulation can be held prior to biopsy as per investigator). Patients on aspirin and other platelet agents are eligible. secondary trial: Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients who will be therapeutically anticoagulated with heparins or coumadin at the time of the biopsy (they are eligible if anticoagulation can be held prior to biopsy as per investigator). Patients on aspirin and other platelet agents are eligible. secondary trial: Peripheral neuropathy grade 2 at randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients who will be therapeutically anticoagulated with heparins or coumadin at the time of the biopsy (they are eligible if anticoagulation can be held prior to biopsy as per investigator). Patients on aspirin and other platelet agents are eligible. secondary trial: Active cardiac disease the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients who will be therapeutically anticoagulated with heparins or coumadin at the time of the biopsy (they are eligible if anticoagulation can be held prior to biopsy as per investigator). Patients on aspirin and other platelet agents are eligible. secondary trial: History of cardiac dysfunction the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients who will be therapeutically anticoagulated with heparins or coumadin at the time of the biopsy (they are eligible if anticoagulation can be held prior to biopsy as per investigator). Patients on aspirin and other platelet agents are eligible. secondary trial: Any malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients who will be therapeutically anticoagulated with heparins or coumadin at the time of the biopsy (they are eligible if anticoagulation can be held prior to biopsy as per investigator). Patients on aspirin and other platelet agents are eligible. secondary trial: Known hypersensitivity to any study medication the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients who will be therapeutically anticoagulated with heparins or coumadin at the time of the biopsy (they are eligible if anticoagulation can be held prior to biopsy as per investigator). Patients on aspirin and other platelet agents are eligible. secondary trial: Breastfeeding or pregnant the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with known immunodeficiency or receiving immunosuppressive therapies. secondary trial: Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with known immunodeficiency or receiving immunosuppressive therapies. secondary trial: HER2+ status defined as IHC 3+ staining or in situ hybridization positive the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with known immunodeficiency or receiving immunosuppressive therapies. secondary trial: Patients with resistance to trastuzumab the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with known immunodeficiency or receiving immunosuppressive therapies. secondary trial: Prior taxane therapy the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with known immunodeficiency or receiving immunosuppressive therapies. secondary trial: Patients with an ECOG performance status of 0 - 2 the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with known immunodeficiency or receiving immunosuppressive therapies. secondary trial: Patients with measurable disease as per RECIST criteria the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with known immunodeficiency or receiving immunosuppressive therapies. secondary trial: Documentation of negative pregnancy test for patients of child bearing potential prior to enrollment within 7 days prior to randomization. Sexually active pre-menopausal women must use adequate contraceptive measures, excluding estrogen containing contraceptives, while on study; the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with known immunodeficiency or receiving immunosuppressive therapies. secondary trial: Patients must meet laboratory criteria defined in the study within 21 days prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with known immunodeficiency or receiving immunosuppressive therapies. secondary trial: Prior mTOR inhibitors or vinca alkaloid agents for the treatment of cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with known immunodeficiency or receiving immunosuppressive therapies. secondary trial: More than three prior chemotherapy lines for advanced disease. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with known immunodeficiency or receiving immunosuppressive therapies. secondary trial: Symptomatic CNS metastases or evidence of leptomeningeal disease. Previously treated asymptomatic CNS metastases are allowed provided that the last treatment for CNS metastases was completed >8 weeks prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with known immunodeficiency or receiving immunosuppressive therapies. secondary trial: Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with known immunodeficiency or receiving immunosuppressive therapies. secondary trial: Peripheral neuropathy grade 2 at randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with known immunodeficiency or receiving immunosuppressive therapies. secondary trial: Active cardiac disease the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with known immunodeficiency or receiving immunosuppressive therapies. secondary trial: History of cardiac dysfunction the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with known immunodeficiency or receiving immunosuppressive therapies. secondary trial: Any malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with known immunodeficiency or receiving immunosuppressive therapies. secondary trial: Known hypersensitivity to any study medication the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Patients with known immunodeficiency or receiving immunosuppressive therapies. secondary trial: Breastfeeding or pregnant the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: History of allergic reactions to imiquimod or its excipients. secondary trial: Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: History of allergic reactions to imiquimod or its excipients. secondary trial: HER2+ status defined as IHC 3+ staining or in situ hybridization positive the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: History of allergic reactions to imiquimod or its excipients. secondary trial: Patients with resistance to trastuzumab the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: History of allergic reactions to imiquimod or its excipients. secondary trial: Prior taxane therapy the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: History of allergic reactions to imiquimod or its excipients. secondary trial: Patients with an ECOG performance status of 0 - 2 the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: History of allergic reactions to imiquimod or its excipients. secondary trial: Patients with measurable disease as per RECIST criteria the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: History of allergic reactions to imiquimod or its excipients. secondary trial: Documentation of negative pregnancy test for patients of child bearing potential prior to enrollment within 7 days prior to randomization. Sexually active pre-menopausal women must use adequate contraceptive measures, excluding estrogen containing contraceptives, while on study; the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: History of allergic reactions to imiquimod or its excipients. secondary trial: Patients must meet laboratory criteria defined in the study within 21 days prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: History of allergic reactions to imiquimod or its excipients. secondary trial: Prior mTOR inhibitors or vinca alkaloid agents for the treatment of cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: History of allergic reactions to imiquimod or its excipients. secondary trial: More than three prior chemotherapy lines for advanced disease. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: History of allergic reactions to imiquimod or its excipients. secondary trial: Symptomatic CNS metastases or evidence of leptomeningeal disease. Previously treated asymptomatic CNS metastases are allowed provided that the last treatment for CNS metastases was completed >8 weeks prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: History of allergic reactions to imiquimod or its excipients. secondary trial: Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: History of allergic reactions to imiquimod or its excipients. secondary trial: Peripheral neuropathy grade 2 at randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: History of allergic reactions to imiquimod or its excipients. secondary trial: Active cardiac disease the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: History of allergic reactions to imiquimod or its excipients. secondary trial: History of cardiac dysfunction the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: History of allergic reactions to imiquimod or its excipients. secondary trial: Any malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: History of allergic reactions to imiquimod or its excipients. secondary trial: Known hypersensitivity to any study medication the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: History of allergic reactions to imiquimod or its excipients. secondary trial: Breastfeeding or pregnant the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Uncontrolled intercurrent medical illness or psychiatric illness/social situations that would limit compliance with study requirements. secondary trial: Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Uncontrolled intercurrent medical illness or psychiatric illness/social situations that would limit compliance with study requirements. secondary trial: HER2+ status defined as IHC 3+ staining or in situ hybridization positive the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Uncontrolled intercurrent medical illness or psychiatric illness/social situations that would limit compliance with study requirements. secondary trial: Patients with resistance to trastuzumab the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Uncontrolled intercurrent medical illness or psychiatric illness/social situations that would limit compliance with study requirements. secondary trial: Prior taxane therapy the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Uncontrolled intercurrent medical illness or psychiatric illness/social situations that would limit compliance with study requirements. secondary trial: Patients with an ECOG performance status of 0 - 2 the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Uncontrolled intercurrent medical illness or psychiatric illness/social situations that would limit compliance with study requirements. secondary trial: Patients with measurable disease as per RECIST criteria the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Uncontrolled intercurrent medical illness or psychiatric illness/social situations that would limit compliance with study requirements. secondary trial: Documentation of negative pregnancy test for patients of child bearing potential prior to enrollment within 7 days prior to randomization. Sexually active pre-menopausal women must use adequate contraceptive measures, excluding estrogen containing contraceptives, while on study; the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Uncontrolled intercurrent medical illness or psychiatric illness/social situations that would limit compliance with study requirements. secondary trial: Patients must meet laboratory criteria defined in the study within 21 days prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Uncontrolled intercurrent medical illness or psychiatric illness/social situations that would limit compliance with study requirements. secondary trial: Prior mTOR inhibitors or vinca alkaloid agents for the treatment of cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Uncontrolled intercurrent medical illness or psychiatric illness/social situations that would limit compliance with study requirements. secondary trial: More than three prior chemotherapy lines for advanced disease. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Uncontrolled intercurrent medical illness or psychiatric illness/social situations that would limit compliance with study requirements. secondary trial: Symptomatic CNS metastases or evidence of leptomeningeal disease. Previously treated asymptomatic CNS metastases are allowed provided that the last treatment for CNS metastases was completed >8 weeks prior to randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Uncontrolled intercurrent medical illness or psychiatric illness/social situations that would limit compliance with study requirements. secondary trial: Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Uncontrolled intercurrent medical illness or psychiatric illness/social situations that would limit compliance with study requirements. secondary trial: Peripheral neuropathy grade 2 at randomization the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Uncontrolled intercurrent medical illness or psychiatric illness/social situations that would limit compliance with study requirements. secondary trial: Active cardiac disease the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Uncontrolled intercurrent medical illness or psychiatric illness/social situations that would limit compliance with study requirements. secondary trial: History of cardiac dysfunction the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Uncontrolled intercurrent medical illness or psychiatric illness/social situations that would limit compliance with study requirements. secondary trial: Any malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Uncontrolled intercurrent medical illness or psychiatric illness/social situations that would limit compliance with study requirements. secondary trial: Known hypersensitivity to any study medication the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Uncontrolled intercurrent medical illness or psychiatric illness/social situations that would limit compliance with study requirements. secondary trial: Breastfeeding or pregnant the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |
b97d9465-db14-43af-9451-4b824e67abb8 | primary trial: Pregnancy or lactation. secondary trial: Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent. the primary trial and the secondary trial use different inclusion criteria for their cohorts, so patients may be eligible for one cohort, but not the other. | 0 |